AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00903448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevacid
Description: Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
Study NCT05124197 — intervention group
Intervention type: OTHER
Intervention: prone position
Description: extension of prone position duration
Study NCT01630213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 + fish oil/fish oil placebo
Description: Vitamin D3 2000 IU/day and fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo per day
Study NCT01630213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo + fish oil/fish oil placebo
Description: Vitamin D3 placebo/day + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo/day
Study NCT04111406 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Current practice
Description: Epidural insertion and epidural drug administration depend on anesthetist in charge
Study NCT04111406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protocol based
Description: Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based~1. insertion at mid-level of surgical insertion~2. insertion depth is 3-5 cm in space, not more than 5 cm~3. using benzoin tincture and transparent dressing to fix catheter~4. test dose with 2%xylocaine with adrenaline 1:200,000 3ml If not cover desired dermatome: 2% lidocaine with adr added 3 ml every 5 min (up to 2 times)~5. After induction and patients' hemodynamic are stable. Load 2 mg morphine with 0.0625% bupivacaine + morphine 0.02 mg/ml 3 ml then continuous infusion with rate according to initial local anesthetic requirement for incisional area coverage
Study NCT02715206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: keepin' it REAL classic
Description: keepin' it REAL consists of 10 classroom lessons implemented in 7th grade and 4 booster sessions implemented in 8th grade by the classroom teacher following training
Study NCT02715206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: keepin' it REAL rural
Description: keepin' it REAL rural drug prevention curriculum consists for 10 lessons taught in 7th grade and 4 booster sessions taught in 8th grade.
Study NCT02715206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control
Description: control group continues to teach whatever prevention curriculum they were using prior to study
Study NCT00703573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-777469 400 mg
Description: S-777469 400 mg BID
Study NCT00703573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-777469 800 mg
Description: S-777469 800 mg BID
Study NCT00703573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo BID
Study NCT00703573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study NCT02135653 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Study NCT02135653 — intervention group
Intervention type: OTHER
Intervention: Eischens Yoga
Study NCT01839630 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
Study NCT01567748 — intervention group
Intervention type: PROCEDURE
Intervention: BP Measurements at aorta, radial and femoral locations
Description: The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
Study NCT00626314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: myoblast
Description: autologous myoblast
Study NCT00626314 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: sham
Description: sham injection procedure
Study NCT05221424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: The training program about hypertension prepared according to the Roy Adaptation Model was performed in a room in the cardiology outpatient clinic of a state hospital. The training content was shaped according to 4 (four) basic areas of the Roy Adaptation Model (physiological field, self-concept field, role function field and interdependence field). The training taught to each patient individually and interactively with the support of powerpoint presentation lasted for averagely 45-50 minutes. A Hypertension Training Booklet was prepared according to the Roy Adaptation Model in order to be used during the training and to strengthen the training.
Study NCT01642199 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Intensity Behavioral Weight Loss + Peer Health Coach
Description: Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
Study NCT01642199 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Intensity Behavioral Weight Loss + Mentor Health Coach
Description: Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
Study NCT01642199 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Intensity Behavioral Weight Loss
Description: Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
Study NCT03690882 — intervention group
Intervention type: OTHER
Intervention: systematic review of medical imaging
Study NCT01957228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone biopsies
Study NCT03248453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoPS
Description: The COPS is an automated and objective computer-based program which generate a score/number after the colonoscope has reached the cecum. The participants are able to compare the score with experts.
Study NCT01196078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg, orally once a day for up to 6 cycles of 21 days each
Study NCT01196078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine
Description: 60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
Study NCT02881060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Study NCT02881060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodon bitartrate-acetaminophen arm 1
Description: Tablet orally administered under fasted conditions
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodon bitartrate-acetaminophen arm 2
Description: Tablet orally administered under fed conditions
Study NCT04538430 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SPRINT percutaneous peripheral nerve stimulator placed
Description: Placement of a SPRINT percutaneous peripheral nerve stimulator targeting the bilateral medial branches at the suspected level of pain generation. This procedure is done as standard of care.
Study NCT01728909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
Study NCT01728909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study NCT01234285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
Study NCT01234285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
Study NCT04435743 — intervention group
Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide is given as any following dosage:~1. 25mg, PO QD, Day 1-10 in every 21 days for 6 cycles;~2. 15mg, PO QD, Day 1-14 in every 21 days for 6 cycles;~3. 25mg, PO QD, Day 1-10 in every 21 days for 1 year;~4. 25mg, PO QD, Day 1-21 in every 28 days for 1 year;~5. 25mg, PO QD, Day 1-10 in every 28 days for 12 cycles;~6. 20mg, PO QD, Day 1-21 in every 28 days for 12 cycles.
Study NCT04151095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTL Exercise Training
Description: Participants will complete exercise training on a recumbent bike placed on flat ground (CTL).
Study NCT01545609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: Text messages to cell phone with education messages about the specific birth control they are using
Study NCT00126789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal Matrix Patch ZR-02-01
Description: ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
Study NCT03090464 — intervention group
Intervention type: OTHER
Intervention: Use of digital disease management tool
Description: The purpose of the study is to evaluate if the provision of a digital disease management tool, in addition to SOC for T2DM, will improve glycemic control. The impact of the tool will be assessed in comparison to a Control group who will receive SOC alone. All participants will complete the PRO assessments. This is a real world study carried out at the point of care.
Study NCT00928356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid CABG/PCI
Description: Same sitting hybrid, robotic CABG/PCI
Study NCT00928356 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Off Pump CABG
Description: Standard of Care Off Pump CABG
Study NCT03771599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Traditional massage of thirty minutes duration ( five minutes of massage was provided to all four limbs, front and back of trunk area) prior to routine physical therapy.~Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.
Study NCT03771599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.
Study NCT03849105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4-L-[131I]iodo-phenylalanine (131I-IPA)
Description: Study participants will receive by intravenous infusion an escalating activity of 4-L-\[131I\]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy
Study NCT00154349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study NCT03910647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole
Description: effect of this drug on renal function
Study NCT03569943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot Based Transtympanic drain placement
Description: Placement of a transtympanic drain with a robot based device assistance called RobOtol
Study NCT00659282 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
Study NCT00256126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen
Description: Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month
Study NCT00256126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen
Description: Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.
Study NCT01864824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl donor
Description: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
Study NCT01394380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: artificially sweetened sodas
Description: subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
Study NCT04473001 — intervention group
Intervention type: OTHER
Intervention: Continuous vital signs and glucose monitoring
Description: The patients will have the following parameters and vital signs continuously monitored using wireless equipment:~* Glucose measurements (quasi-continuous, every 5 minutes)~* Heart rate~* Heart rhythm (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Signs of cardiac ischemia (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Respiration rate~* Oxygen saturation of arterial hemoglobin (%SpO2)~* Perfusion index (ratio of the pulsatile blood flow to the non-pulsatile or static blood in peripheral tissue)~* Blood pressure (quasi-continuous; every 30-60 minutes)~* Skin temperature~* Electrodermal activity~* Ambulatory activity (accelerometry)
Study NCT00387088 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Respimat
Study NCT00387088 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium
Study NCT04034134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: 50 mg twice-daily (BID)
Study NCT04034134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: 150 mg quaque die (QD)
Study NCT04034134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: 200 mg quaque die (QD)
Study NCT04097990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels
Study NCT02280993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHAP
Description: DHAP
Study NCT02280993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin
Study NCT02280993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Peripheral Blood Stem Cell Transplantation
Description: Autologous Peripheral Blood Stem Cell Transplantation
Study NCT02054637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Study NCT01500317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol
Description: Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.
Study NCT01500317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.
Study NCT01500317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received placebo three times per day (tid) for 48 hours.
Study NCT00827229 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Labor Monitor
Study NCT00102661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: 15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
Study NCT03263403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ingovax ACWY
Description: The pharmaceutical company in Bangladesh is now currently marketing meningococcal vaccine of Yuxi Walvax Biotechnology Co. Ltd which is filled finish by Incepta Vaccines Ltd. This fill finish meningococcal vaccine is already registered and licensed in Bangladesh. However, at present, no locally produced meningococcal vaccine is available in Bangladesh. Once this clinical trial is completed, it will then proceed for registration and licensure in Bangladesh. Ingovax ACWY is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis Group A, Group C, Group Y and Group W135. When reconstituted, the vaccine is a clear, colorless sterile solution for subcutaneous use.
Study NCT01234285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
Study NCT01234285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: 5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
Study NCT03263403 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadri Meningo
Description: Meningococcal polysaccharide vaccine Quadri Meningo vaccine manufactured by BiO-MeD Private Limited. Quadri Meningo \[Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined\] is a freeze-dried preparation of the Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y, and Group W-135. After reconstitution with diluent, the vaccine is a clear colourless liquid.
Study NCT02015403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care + NAC (N -ACETYLCYSTEINE)
Study NCT02015403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (in control arm)
Study NCT02015403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care (in control arm)
Study NCT06250764 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical periodontal measuremenets
Description: The periodontal assessment was performed by a single trained examiner (S.D.). A graded periodontal probe (Williams, Hu-Friedy, Chicago, IL, USA) was used to measure probing depth (PD) which was determined as the depth from the gingival margin to the bottom of the gingival sulcus/periodontal pocket, clinical attachment loss (CAL) which was calculated as the distance from the cemento-enamel junction to the bottom of the periodontal pocket and dual recording (+/-) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) in total except third molars G
Study NCT01864824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01140893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.~From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time.
Study NCT01140893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03584360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone-Calcipotriene Topical
Description: Comparison between betamethasone-calcipotriol and placebo
Study NCT04438252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICDAS II
Description: Index for caries detection
Study NCT06250764 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA test from gingival crevicular fluid (GCF)
Description: GCF sampled from the buccal aspects of non-contiguous proximal regions in maxillary single-rooted teeth. In the periodontitis groups, fluid samples were taken from the two deepest pockets. In the gingivitis and periodontal healthy groups, fluid samples were obtained from areas with and without visible inflammation, respectively